eb513503b5
- Source: inbox/queue/2025-xx-neda-anad-glp1-eating-disorders-clinical-guidance.md - Domain: health - Claims: 2, Entities: 2 - Enrichments: 3 - Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5) Pentagon-Agent: Vida <PIPELINE>
1.7 KiB
1.7 KiB
| title | type | entity_type | domain | status |
|---|---|---|---|---|
| National Association of Anorexia Nervosa and Associated Disorders (ANAD) | entity | organization | health | active |
National Association of Anorexia Nervosa and Associated Disorders (ANAD)
Oldest U.S. eating disorder advocacy organization, founded 1976. Provides clinical guidance, support groups, and treatment resources.
Timeline
- 2025-01-01 — Published joint clinical guidance with NEDA on GLP-1 receptor agonist use in eating disorder populations, documenting that GI side effects 'can trigger or worsen purging behaviors' and recommending tri-specialist care teams with hydration/electrolyte monitoring
Overview
ANAD focuses on eating disorder treatment access, clinical standards, and patient advocacy. Their guidance documents clinical best practices but carries no regulatory authority.
Key Clinical Positions
GLP-1 Monitoring Requirements (2025):
- Hydration and electrolyte levels (vomiting + GI side effects pose serious risk)
- Emergence of restrictive eating behaviors
- Weight loss rate and magnitude
- Eating disorder symptom changes via standardized measures
Required Care Team:
- Physician versed in GLP-1s and eating disorders
- Therapist experienced with both GLP-1s and ED treatment
- Dietitian familiar with this medication class and recovery nutrition
Documented Risks: ANAD notes that GI side effects (nausea, vomiting, diarrhea, gastroparesis) 'can trigger or worsen purging behaviors' in vulnerable individuals, creating a direct pharmacological harm pathway. Approximately 2/3 of weight loss returns within one year if medication stops, creating weight cycling risk particularly harmful for ED populations.